← Oncology Approval Tracker

FDA DECISION ·

Welireg

belzutifan · Merck

FDA approvalIndication revisionRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Clarifies the existing use to adults with advanced renal cell carcinoma that has a clear-cell component following prior PD-1 or PD-L1 inhibition and VEGF tyrosine kinase inhibitor therapy.

LAMPGEN ANALYSIS

Why it matters

The revised label explicitly identifies the histology represented by the pivotal evidence.

What research teams should watch

Confirm the clear-cell component and both prior drug classes before using the revised eligibility criteria.

PRIMARY RECORDS

Sources